Evolus, Inc. (EOLS): who owns it and who trades it
As of Nov 16, 2026, EOLS insiders reported 7 open-market sales worth $1.8M and no purchases in the last 12 months, with 48% of the sale value made under pre-set 10b5-1 plans. The largest seller was David Moatazedi (Director), with $1.7M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Evolus
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns EOLS
157 funds and institutions reported EOLS shares worth $388M at the end of Q2 2026, about 85% of the company. The largest holder is Nantahala Capital Management, LLC with 17.0%.
Funds and institutions (13F) 85%Everyone else 15%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 11.20M | 17.01% | $77.8M | +76% |
| BlackRock, Inc. | 4.84M | 7.35% | $33.6M | +13% |
| Braidwell LP | 3.16M | 4.79% | $21.9M | +2% |
| Frazier Life Sciences Management, L.P. | 2.63M | 3.99% | $18.3M | No change |
| Perceptive Advisors LLC | 2.46M | 3.73% | $17.1M | +91% |
| Vanguard Capital Management LLC | 2.36M | 3.59% | $16.4M | -4% |
| Assenagon Asset Management S.A. | 1.82M | 2.76% | $12.6M | +204% |
| Millennium Management LLC | 1.79M | 2.71% | $12.4M | +22% |
| State Street Corp | 1.70M | 2.58% | $11.8M | +29% |
| Geode Capital Management, LLC | 1.61M | 2.44% | $11.2M | +16% |
| Stonepine Capital Management, LLC | 1.59M | 2.41% | $11M | -10% |
| Point72 Asset Management, L.P. | 1.51M | 2.29% | $10.5M | – |
| Pinnacle Associates Ltd | 1.49M | 2.26% | $10.3M | +28% |
| Armistice Capital, LLC | 1.44M | 2.18% | $10M | +3% |
| Rice Hall James & Associates, LLC | 1.29M | 1.96% | $9M | +3% |
| AWH Capital, L.P. | 1.25M | 1.90% | $8.7M | +100% |
| Goldman Sachs Group Inc | 1.22M | 1.85% | $8.5M | +12% |
| Soleus Capital Management, L.P. | 822,428 | 1.25% | $5.7M | -63% |
| Soviero Asset Management, LP | 770,000 | 1.17% | $5.3M | +13% |
| UBS Group AG | 752,679 | 1.14% | $5.2M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, EOLS insiders reported $0 of open-market purchases and $1.8M of sales. 48% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | David Moatazedi | Director | Sale | 105,108 | $9.04 | $950K | Form 4 |
| Mar 20, 2026 | Rui Avelar | See Remarks | Sale | 3,119 | $4.75 | $14.8K | Form 4 |
| Mar 20, 2026 | David Moatazedi | Director | Sale plan | 13,669 | $4.75 | $64.9K | Form 4 |
| Mar 17, 2026 | David Moatazedi | Director | Sale plan | 116,720 | $4.89 | $571K | Form 4 |
| Mar 17, 2026 | Rui Avelar | See Remarks | Sale plan | 29,996 | $4.89 | $147K | Form 4 |
| Dec 22, 2025 | David Moatazedi | Director | Sale plan | 10,539 | $7.15 | $75.4K | Form 4 |
| Dec 22, 2025 | Rui Avelar | See Remarks | Sale plan | 2,261 | $7.15 | $16.2K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| David Moatazedi | See Remarks, Director | – | $1.7M | Sep 2, 2026 |
| Rui Avelar | See Remarks | – | $178K | Mar 20, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
EOLS short interest
Moderate short interest. 9.1% of EOLS shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 2%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.02M EOLS shares were sold short, 9.1% of the shares outstanding, down 6.0% from the report before. At the average daily volume of 642,143 shares, buying them all back would take about 9.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.02M | 9.10% | -6% | 642,143 | 9.4 |
| Oct 15, 2026 | 6.41M | 9.70% | +14% | 906,582 | 7.1 |
| Sep 30, 2026 | 5.63M | 8.52% | +2% | 603,494 | 9.3 |
| Sep 15, 2026 | 5.53M | 8.37% | +3% | 837,573 | 6.6 |
| Aug 31, 2026 | 5.37M | 8.13% | -8% | 1.03M | 5.2 |
| Aug 14, 2026 | 5.85M | 8.86% | +5% | 1.34M | 4.4 |
| Jul 31, 2026 | 5.57M | 8.43% | -6% | 637,372 | 8.7 |
| Jul 15, 2026 | 5.91M | 8.97% | -2% | 805,874 | 7.3 |
| Jun 30, 2026 | 6.02M | 9.14% | +2% | 824,575 | 7.3 |
| Jun 15, 2026 | 5.90M | 8.95% | -3% | 733,042 | 8.0 |
| May 29, 2026 | 6.06M | 9.20% | -2% | 741,098 | 8.2 |
| May 15, 2026 | 6.17M | 9.37% | -7% | 1.16M | 5.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Evolus company events
Evolus filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Aug 4, 2026AgreementEvolus Pharma B.V., a wholly owned subsidiary of Evolus, Inc., and Symatese Aesthetics S.A.S. entered into an amendment to the License, Supply and Distribution Agreement dated December 20, 2023, which the Company previously disclosed in a Current Report on Form 8-K filed on December 20, 2023. Filing
- Jul 8, 2026AgreementEvolus, Inc. and IBSA Institut Biochimique SA entered into a License, Supply and Distribution Agreement, pursuant to which IBSA granted to the Company an exclusive right and license to develop, commercialize and distribute Profhilo ®, an injectable hyaluronic acid product for skin-quality… Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- May 4, 2026ResultsReleased financial results. Filing
- Mar 13, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers. Filing
- Mar 3, 2026AgreementEvolus, Inc. entered into a Loan and Security Agreement with Eclipse Business Capital LLC, as administrative agent and the lenders party thereto. Filing
- Jan 9, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Evolus financials
Famous investors that hold EOLS
4 of the 50 well-known investors we track reported holding EOLS in their latest 13F filing. The largest position is Israel Englander's, worth $13.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.65M | $13.2M | 0.0% | -8% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 710,596 | $5.7M | 0.0% | +135% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 52,384 | $419K | 0.0% | -90% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 26,824 | $215K | 0.0% | -15% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named EOLS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 9, 2026 | Soleus Capital Master Fund, L.P. | 13G/A | 7.7% |
| Nov 9, 2026 | Soleus Capital Master Fund, L.P. | 13G/A | 7.7% |
Questions about Evolus, Inc. (EOLS) stock
Who owns the most EOLS stock?
The largest reported owner of Evolus, Inc. (EOLS) is Nantahala Capital Management, LLC, with 17.0% of the company. In total, 157 funds and institutions reported holding EOLS at the end of Q2 2026, together about 85% of the shares. See the largest owners.
Are EOLS insiders buying or selling?
In the last 12 months, EOLS insiders reported no open-market purchases and 7 sales worth $1.8M. The latest trade was on Sep 2, 2026. See every trade.
What is the short interest in EOLS?
As of Oct 30, 2026, 6.02M EOLS shares were sold short, 9.1% of the shares outstanding, down 6.0% from the report before. At the average daily volume of 642,143 shares, buying them all back would take about 9.4 trading days (days to cover). See the history.
Which famous investors hold EOLS?
4 of the 50 well-known investors we track reported EOLS in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $13.2M. See all holders.
Executive pay
Evolus's chief executive was paid a total of $6.4M for the year ended Dec 31, 2025, down 8% from $7M the year before. In the last 12 months, Evolus's executives and directors bought no stock on the open market and sold $1.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.